ES2043998T3 - El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes. - Google Patents

El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes.

Info

Publication number
ES2043998T3
ES2043998T3 ES89117031T ES89117031T ES2043998T3 ES 2043998 T3 ES2043998 T3 ES 2043998T3 ES 89117031 T ES89117031 T ES 89117031T ES 89117031 T ES89117031 T ES 89117031T ES 2043998 T3 ES2043998 T3 ES 2043998T3
Authority
ES
Spain
Prior art keywords
inositoltrisphosphate
preparation
related disorders
medication against
against transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89117031T
Other languages
English (en)
Inventor
Matti Siren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perstorp AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Application granted granted Critical
Publication of ES2043998T3 publication Critical patent/ES2043998T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION RELATA EL USO DE AL MENOS UN ISOMERO INOSITOLTRIFOSFATO (IP3) PARA PREPARAR UN MEDICAMENTO QUE PREVENGA, ALIVIE O COMBATA COMPLICACIONES EN RELACION A TRANSPLANTES.
ES89117031T 1988-09-15 1989-09-14 El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes. Expired - Lifetime ES2043998T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803248A SE464059C (sv) 1988-09-15 1988-09-15 Användning av inositoltrifosfat för framställning av läkemedel

Publications (1)

Publication Number Publication Date
ES2043998T3 true ES2043998T3 (es) 1994-01-01

Family

ID=20373330

Family Applications (5)

Application Number Title Priority Date Filing Date
ES89117031T Expired - Lifetime ES2043998T3 (es) 1988-09-15 1989-09-14 El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes.
ES89117032T Expired - Lifetime ES2054965T3 (es) 1988-09-15 1989-09-14 El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.
ES89117030T Expired - Lifetime ES2055772T3 (es) 1988-09-15 1989-09-14 Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.
ES89117028T Expired - Lifetime ES2045319T3 (es) 1988-09-15 1989-09-14 El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
ES89117029T Expired - Lifetime ES2073419T3 (es) 1988-09-15 1989-09-14 Uso de inositatrifosfato en la preparacion de un medicamento contra la diabetes.

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES89117032T Expired - Lifetime ES2054965T3 (es) 1988-09-15 1989-09-14 El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.
ES89117030T Expired - Lifetime ES2055772T3 (es) 1988-09-15 1989-09-14 Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.
ES89117028T Expired - Lifetime ES2045319T3 (es) 1988-09-15 1989-09-14 El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
ES89117029T Expired - Lifetime ES2073419T3 (es) 1988-09-15 1989-09-14 Uso de inositatrifosfato en la preparacion de un medicamento contra la diabetes.

Country Status (8)

Country Link
EP (5) EP0359257B1 (es)
JP (5) JPH02191218A (es)
AT (5) ATE104855T1 (es)
DE (5) DE68914922T2 (es)
ES (5) ES2043998T3 (es)
GB (5) GB2223404B (es)
GR (4) GR3005448T3 (es)
SE (2) SE464059C (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5427956A (en) * 1989-03-08 1995-06-27 The University Of Virginia Patent Foundation Quantitative analysis for diabetic condition predictor
US5428066A (en) * 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
US5750348A (en) * 1989-03-08 1998-05-12 The University Of Virginia Patents Foundation Method for detecting insulin resistance
WO1990010439A1 (en) * 1989-03-08 1990-09-20 The University Of Virginia Alumni Patents Foundation Dietary supplement for insulin-resistant diabetics
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
SE467340B (sv) * 1990-07-04 1992-07-06 Perstorp Ab Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist
JP2750239B2 (ja) * 1991-08-14 1998-05-13 三共株式会社 アデノホスチンａまたはｂならびにその製法
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
SE9600194D0 (sv) * 1996-01-19 1996-01-19 Perstorp Ab A new chemical compound
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9602463D0 (sv) * 1996-06-24 1996-06-24 Perstorp Ab The use of growth factor modulating compounds
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
US6486127B1 (en) 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
KR100653557B1 (ko) * 2001-10-06 2006-12-05 아미코젠주식회사 카이로 이노시톨 또는 피니톨의 백내장 예방치료제로서의용도와 그 조성물
US11446317B2 (en) * 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel

Also Published As

Publication number Publication date
ATE84719T1 (de) 1993-02-15
GB2223167A (en) 1990-04-04
GB2223404A (en) 1990-04-11
GR3005448T3 (es) 1993-05-24
GB2223404B (en) 1992-04-08
GB2223168B (en) 1992-08-12
JP3058334B2 (ja) 2000-07-04
JPH02191220A (ja) 1990-07-27
JP2547257B2 (ja) 1996-10-23
EP0359257A2 (en) 1990-03-21
EP0359256A2 (en) 1990-03-21
JPH02191217A (ja) 1990-07-27
DE68922165D1 (de) 1995-05-18
GR3006825T3 (es) 1993-06-30
JPH02191218A (ja) 1990-07-27
SE9003395L (sv) 1992-04-25
EP0359259A2 (en) 1990-03-21
DE68906106D1 (de) 1993-05-27
GB2223169B (en) 1992-04-08
GB2223168A (en) 1990-04-04
GB8920806D0 (en) 1989-11-01
JPH02191221A (ja) 1990-07-27
SE9003395D0 (sv) 1990-10-24
EP0359256B1 (en) 1993-01-20
DE68914922T2 (de) 1994-09-01
EP0359257B1 (en) 1995-04-12
GB8920811D0 (en) 1989-11-01
EP0359257A3 (en) 1990-10-03
GB8920805D0 (en) 1989-11-01
ES2045319T3 (es) 1994-01-16
EP0359258A3 (en) 1990-10-03
DE68904507T2 (de) 1993-06-09
EP0359258B1 (en) 1994-04-27
EP0359259B1 (en) 1992-08-19
JP2859319B2 (ja) 1999-02-17
ATE79542T1 (de) 1992-09-15
SE464059B (sv) 1991-03-04
DE68902526T2 (de) 1993-03-11
ATE88347T1 (de) 1993-05-15
ES2073419T3 (es) 1995-08-16
DE68914922D1 (de) 1994-06-01
ATE104855T1 (de) 1994-05-15
ES2055772T3 (es) 1994-09-01
GB2223403B (en) 1992-02-26
EP0359258A2 (en) 1990-03-21
EP0359260B1 (en) 1993-04-21
EP0359260A3 (en) 1990-10-03
GR3015764T3 (en) 1995-07-31
DE68902526D1 (de) 1992-09-24
GB8920804D0 (en) 1989-11-01
JP2859318B2 (ja) 1999-02-17
GB2223403A (en) 1990-04-11
DE68904507D1 (de) 1993-03-04
ATE120958T1 (de) 1995-04-15
DE68906106T2 (de) 1993-10-21
DE68922165T2 (de) 1995-09-14
GR3007686T3 (es) 1993-08-31
SE8803248L (sv) 1990-03-16
EP0359260A2 (en) 1990-03-21
GB8920807D0 (en) 1989-11-01
ES2054965T3 (es) 1994-08-16
SE464059C (sv) 1997-06-02
SE8803248D0 (sv) 1988-09-15
GB2223167B (en) 1992-02-26
EP0359256A3 (en) 1990-10-10
GB2223169A (en) 1990-04-04
JPH02191219A (ja) 1990-07-27
EP0359259A3 (en) 1990-10-03

Similar Documents

Publication Publication Date Title
ES2054965T3 (es) El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.
ES2093636T3 (es) Uso de un compuesto de 15-ceto-prostaglandina para la mejora de la funcion encefalica.
MX9207222A (es) Procedimiento para la preparacion de compuestos farmaceuticos que reducen selectivamente el nivel de lipidos de la sangre.
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
ES2091766T3 (es) Uso de n-butil-desoxinojirimicina para el tratamiento de herpes.
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
PT97052A (pt) Processo para a preparacao de composicoes farmaceuticas contendo bambuterol, apropriadas para diminuir o teor de lipidos no sangue
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
MX9202987A (es) Analogos de insulina, formulacion farmaceutica que los contiene y procedimiento para obtener dichos analogos.
ES2161745T3 (es) Utilizacion de la trimetazidina para la obtencion de medicamentos destinados para el tratamiento de los trastornos relacionados con la nefrotoxicidad de la ciclosporina a.
ES2059181T3 (es) Uso de 1,4-dihidropiridinas para la fabricacion de un medicamento para el tratamiento de neuropatias causadas por diabetes mellitus.
NO994930D0 (no) Preventiver og hjelpemidler for ulcerös kolitt og/eller crohn's sykdom
IT9003745A0 (it) Ago a farfalla di sicurezza per uso medicale.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 359259

Country of ref document: ES